Faithful chromosome segregation during mitosis depends on the spindle assembly checkpoint (SAC), which monitors kinetochore attachment to the mitotic spindle. Unattached kinetochores generate mitotic checkpoint proteins complexes (MCCs) that bind and inhibit the anaphase-promoting complex, or cyclosome (APC/C). How the SAC proficiently inhibits the APC/C but still allows its rapid activation when the last kinetochore attaches to the spindle is important for the understanding of how cells maintain genomic stability. We show that the APC/C subunit APC15 is required for the turnover of the APC/C co-activator CDC20 and release of MCCs during SAC signalling but not for APC/C activity per se. In the absence of APC15, MCCs and ubiquitylated CDC20 remain 'locked' onto the APC/C, which prevents the ubiquitylation and degradation of cyclin B1 when the SAC is satisfied. We conclude that APC15 mediates the constant turnover of CDC20 and MCCs on the APC/C to allow the SAC to respond to the attachment state of kinetochores.
RESULTS

APC15 is a subunit of the human APC/C
We identified APC15 in a systematic proteomic analysis of the APC/C purified from HeLa cell extracts. Human APC15 is conserved in animals and has sequence similarity to the Schizosaccharomyces pombe APC/C subunit Apc15 (ref. 6) and Saccharomyces cerevisiae Mnd2 (ref. 7) ; therefore, we named it APC15 ( Supplementary Fig. S1a ).
To characterize APC15, we used recombinant human APC15 to raise a polyclonal antibody that recognized a protein of the predicted relative molecular mass (14,300) on immunoblots from HeLa cell extracts whose abundance was decreased after siRNA treatment with APC15-specific oligonucleotides, and co-migrated with recombinant APC15 (Supplementary Fig. S1b ). All of the detectable APC15 co-precipitated with other APC/C subunits ( using extracts from prometaphase-arrested HeLa cells that were treated with 50 nM of the indicated siRNAs for 72 h. Note that depleting APC6 or APC8 causes the APC/C to dissociate into two subcomplexes 13 , one of which was precipitated with anti-APC4 and the other with anti-APC3 (see schematic, bottom, and Supplementary cell cycle (Fig. 1b) , and co-migrated with them in size-exclusion chromatography (Fig. 1c) . APC15 required APC8 for stability and to be incorporated into the APC/C ( Fig. 1d and Supplementary  Fig. S2a,b) , and in vitro binding assays and the recently published structure of S. cerevisiae APC/C indicated that Mnd2 also associated with Apc8 (refs 7,8) . Moreover, MND2 and CDC23-1 (APC8) mutants are synthetically lethal 9 and human APC15 was detected in APC8-GFP immunoprecipitates 10 .
APC15 depletion delays anaphase and cyclin-B1 degradation
To elucidate the function of APC15 we used five different siRNAs that decreased the abundance of APC15 in HeLa and in hTertimmortalized human retinal pigment epithelial (RPE1) cells (Fig. 2a) . We analysed the effect of depleting APC15 on progress through mitosis in RPE1 cell lines in which the Venus fluorescent protein had been 'knocked-in' to one allele of the cyclin-B1 or cyclin-A2 gene (P.C., O. Naschekina and J.P, manuscript in preparation); therefore, the intensity of the Venus fluorescence was directly correlated with the abundance of endogenous cyclin A2 and B1. Depleting APC15 by any of the siRNA treatments delayed progress from nuclear envelope breakdown (NEBD) to anaphase in cycling cells by at least a factor of two (Fig. 2b , 22 ± 3 min in GAPDH-depleted cells, hereafter referred to as control; 44 ± 21 to 54 ± 28 min in APC15-depleted cells; see Supplementary Table S1 for statistical analyses). This phenotype was caused by the lack of APC15 because siRNA-resistant APC15 eliminated the delay ( Supplementary Fig.  S3c ). In APC15-depleted cells chromosomes aligned at the same time as in controls, but cells subsequently arrested with a well-formed metaphase plate (Fig. 2c) . Assaying cyclin-B1-Venus fluorescence intensity in single cells 11 revealed that APC15-depleted cells initiated cyclin-B1 degradation slightly later and degraded it at a slower rate than did controls ( Fig. 2d and Supplementary Fig. S3a,b) , whereas inactivating the APC/C by depleting APC3 stabilized cyclin B1 and severely delayed mitosis 12, 13 (Figs 2d and 3b). In contrast, depleting APC15 did not seem to affect APC/C activity because the kinetics of cyclin-A2 degradation, a SAC-independent substrate 14 , was largely unchanged, although degradation was slower shortly before anaphase when compared with control cells. The time of this divergence correlated with the satisfaction of the SAC (marked by an asterisk in Fig. 2e) , and maintaining the SAC with dimethylenastron (DMA) also slowed cyclin-A2-Venus degradation (Fig. 2e) . The slowdown in cyclin-A2-Venus degradation in APC15-depleted cells was explained by the prolonged presence of MCCs on the APC/C (see below), which competed with cyclin A2 for CDC20 (ref. 14) .
In agreement with single-cell analyses, immunoblots of APC15-depleted HeLa cells progressing through mitosis showed a delay in cyclin-B1, but not cyclin-A2, degradation, and also revealed that CDC20 was stabilized ( Supplementary Fig. S2c ).
APC15 functions through the SAC but is not required for APC/C activity
CDC20 is degraded when the SAC is active 5, [15] [16] [17] ; therefore, the stabilization of CDC20 and cyclin B1, but not cyclin A2, indicated that depleting APC15 probably perturbed the regulation of the APC/C by the SAC. To investigate this, we assayed APC/C activity in APC15-depleted cells after abrogating the SAC either by co-depleting MAD2 (refs 18,19) , or treating cells with 0.5 µM reversine, an inhibitor of the Mps1 kinase 20 . Both treatments eliminated the metaphase delay (Fig. 3a,b ). This indicated that in the absence of the SAC, APC/C activity was likely to be the same in control and APC15-depleted cells. We confirmed this by treating control and APC15-depleted cells with reversine, which showed that cyclin B1 was degraded with very similar rates in control and APC15-depleted cells (Fig. 3c) , and that the kinetics of cyclin-A2 degradation in control, DMA-treated and APC15-depleted cells were identical (Fig. 3d) .
To support our conclusion that depleting APC15 did not directly affect APC/C activity, we sensitized the APC/C by co-depleting APC15 and another APC/C subunit, APC10. Apc10 deletions in S. cerevisiae are viable but APC/C purified from these cells was less processive in ubiquitylating the B-type cyclin, Clb2 (ref. 21).
To assay APC/C activity independently of the SAC we used reversine and observed that, as predicted, the depletion of APC10 slightly decreased the rate of cyclin-B1-Venus degradation, but co-depleting APC15 and APC10 did not have an additive effect ( Supplementary Fig. S4a ).
To verify that APC15 did not contribute to APC/C activity in the absence of the SAC, we assayed interphase APC/C activity in vitro using purified components 22 . Control and APC15-depleted APC/C showed almost identical activity against cyclin B1 (Fig. 3e) . (e) Left, top, autoradiography of an in vitro ubiquitylation assay using interphase APC/C purified from GAPDH-and APC15-depleted cells. The APC/C was immunoprecipitated using anti-APC3 antibodies, activated with Cdh1, and probed for its ability to ubiquitylate cyclin B1 (amino acids 1-86). Cyclin-B1-Ub(n), ubiquitylated cyclin B1. Bottom, western blot analysis (WB) of the ubiquitylation assay done in parallel. Molecular mass markers are shown on the right. Right, the quantification shows cyclin-B1 ubiquitylation normalized to GAPDH -siRNA APC/C (mean ± s.e.m. from three experiments). Uncropped images of blots are shown in Supplementary Fig. S10 .
NEBD to anaphase
We conclude that depleting APC15 does not affect APC/C activity per se but causes a SAC-dependent delay in both the destruction of cyclin B1 and the initiation of anaphase.
APC15 depletion increases the association between the APC/C and the MCC
To determine how APC15 influenced APC/C activity through the SAC we analysed APC/C and SAC complexes in cells depleted of APC15. As a positive control we compared them with complexes from p31 comet -depleted cells. p31 comet antagonizes the dimerization of the two conformations of MAD2 and is required to inactivate the SAC (refs 23-26 and G. Varetti et al., personal communication). In cells treated with DMA to impose the SAC, depleting APC15 stabilized CDC20 and caused a three-to fourfold increase in the amounts of MAD2 and BUB3, and a twofold increase in BUBR1 and CDC20, bound to the APC/C (Fig. 4a and Supplementary Table S1 ). All of these effects were rescued by expressing a siRNA-resistant APC15 ( Supplementary Fig. S4b ). Depleting p31 comet had a smaller effect and influenced mainly the amount of MAD2 precipitating with the APC/C (Fig. 4a) . We also analysed CDC20 immunoprecipitates from the same extracts to determine the effect on MCCs that were not bound to the APC/C and found that depleting APC15 or p31 comet caused a two-to threefold increase in MAD2 and BUB3 levels co-precipitating with CDC20 (Fig. 4b) . Size-exclusion chromatography confirmed that depleting APC15 enriched MAD2 on the APC/C, and enriched both CDC20 and MAD2 in APC/C-unbound MCCs (control: CDC20 Fig. 4c and Supplementary Fig. S5c ). These experiments indicated that during SAC signalling there was a flux of MCC-CDC20 on and off the APC/C that was blocked in the absence of APC15, and that p31 comet was required for the turnover of APC/C-unbound MCCs. If so, one consequence might be that during the SAC a population of APC/C could briefly be devoid of MCCs (apo-APC/C; ref. 27) and able to bind free CDC20 and degrade some cyclin B1. This could be one explanation for why some cancer cells 'slip' out of mitosis as a consequence of the slow proteolysis of cyclin B1 (refs 28-30). Interfering with APC15 or p31 comet , which should decrease the population of apo-APC/C, provided some support for this model because it markedly decreased the level of mitotic slippage in the presence of 5 µM taxol ( Supplementary Fig. S4c : t 50%slippage in control cells 258 min, in APC15 siRNA cells 1,094 min, in p31 comet -siRNA cells 624 min).
APC15 is required for the release from SAC inhibition
To determine what happens when SAC signalling is turned off we treated cells with the Aurora B inhibitor ZM447439 (ref. 32), which inactivates or satisfies the SAC (ref. 31). Compared with control, ZM447439 treatment did not decrease the NEBD-to-anaphase delay in APC15-depleted cells ( Fig. 5a and Supplementary Table S1 ). This indicated that in the absence of APC15, MCCs might not be released from the APC/C after the SAC had been satisfied. To investigate the requirement for APC15 to dissociate MCCs from the APC/C we released cells from a DMA-block into fresh medium containing MG132 (to block mitotic exit) and monitored the dissociation of SAC proteins from the APC/C over time. Whereas MCCs readily dissociated from the APC/C in control cells, both APC15-and p31 comet depletion stabilized BUBR1, MAD2 and BUB3 on the APC/C (Supplementary Fig. S6a) .
To measure the dissociation of MCC components from the APC/C independently of the variable time required for kinetochores to attach to microtubules and satisfy the SAC, we repeated the experiment in the presence of reversine to inactivate the SAC. Again, depleting APC15 strongly impaired the release of MCCs, whereas p31 comet depletion showed a less pronounced effect ( Fig. 5b and Supplementary Fig.  S6b ), indicating that APC15 and p31 comet might regulate different aspects of the SAC. Indeed, depleting both APC15 and p31 comet had an additive effect on the delay from NEBD to anaphase (97 ± 25 min, Supplementary Fig. S7a ). Importantly, APC15 depletion did not affect the transient interaction of p31 comet with the APC/C, excluding the possibility that p31 comet acts through APC15 to release MCCs from the APC/C ( Supplementary Fig. S7b ,c).
MCC components had been shown to dissociate from the APC/C purified from SAC-arrested cells during in vitro ubiquitylation reactions 4 concomitantly with an increase in cyclin-B1 ubiquitylation ( Supplementary Fig. S6c,d ). We confirmed this result and found that this release also required APC15 because, compared with control, APC/C purified from APC15-depleted cells retained MCCs and these inhibited the ubiquitylation of cyclin B1 (Fig. 5c,d and Supplementary  Fig. S6e,f) . As in vitro ubiquitylation reactions do not contain the components that generate a SAC signal (kinetochores), we conclude that the role of APC15 in the release of the MCC is constitutive and intrinsic to the APC/C. However, we cannot exclude that in vivo on satisfaction of the SAC there is crosstalk between the SAC and the APC/C that might involve APC15.
To provide further evidence that APC15 decreases the level of APC/C activity by retaining MCCs on the APC/C, and not because APC15 directly contributes to APC/C activity, we purified mitotic APC/C from control and APC15-depleted cells that was devoid of MCCs. Therefore, we synchronized HeLa cells and added MG132 and reversine shortly before NEBD. APC/C immunoprecipitates from control and APC15-depleted cells had no detectable BUB3, almost no MAD2 and only marginal amounts of BUBR1, even though APC15 was efficiently depleted (Supplementary Fig. S7d ). In vitro ubiquitylation reactions showed that the mitotic APC/C was equally as active when purified from control or from APC15-depleted cells. In contrast, APC/C from APC11-depleted cells was markedly less active ( Supplementary Fig. S7e ). We conclude that APC15 is not required for APC/C activity in mitosis.
CDC20 ubiquitylation is not required to dissociate MCCs from the APC/C
The ubiquitylation of CDC20 has been proposed to disassemble MCCs by interfering with MAD2 binding through eliciting a conformational change in CDC20, or by direct steric occlusion of the MAD2 binding surface 4 . As APC15 depletion stabilized CDC20 ( Fig. 4a and Supplementary Fig. S2c ) we analysed whether APC15 depletion prevented CDC20 ubiquitylation, which might also explain the elevated amount of MAD2 on the APC/C. In contrast, we found that in the absence of APC15 both ubiquitylated CDC20 and MAD2 were enriched on the APC/C (Fig. 6a,b) , indicating that the ubiquitylation of CDC20 did not disrupt the MCC. This was consistent with our previous observation that a non-ubiquitylatable CDC20 mutant (in which all of the lysines were mutated to arginine) could be released from APC/C-unbound MCCs when the SAC was satisfied 5 . Nevertheless, the mechanism of CDC20 release might differ between APC/C-bound and -unbound MCCs (refs 33,34); therefore, we sought to determine whether a non-ubiquitylatable CDC20 could be released from APC/C-bound complexes.
Our mass spectrometry analysis of the APC/C had identified Lys 490, close to the carboxy terminus of CDC20, as ubiquitylated in prometaphase ( Supplementary Fig. S8a ), in agreement with a recent mass spectrometry study, which reported that the neighbouring Lys 485 could also be ubiquitylated 35 . Mutating just these two lysines to arginine completely prevented ubiquitylation and had no effect on the ability of CDC20 to bind the APC/C (Fig. 6c,d ). Moreover, CDC20
K485/490R dissociated with the other MCC components from the APC/C with comparable efficiency to wild-type CDC20 (Fig. 6c,e) . Therefore, we conclude that CDC20 ubiquitylation is not required to dissociate MAD2 and the MCC from the APC/C.
APC11 contributes to the release of MCCs from the APC/C
To determine whether the increase of MCCs on the APC/C is specific to APC15 depletion, we monitored MCC binding to the APC/C during SAC signalling in the absence of several other APC/C subunits. Depleting APC3 had no effect, whereas depleting APC6 and APC8 strongly decreased the level of MCC binding to the APC/C ( Supplementary Fig. S8b ). This result was expected because we recently showed that APC8 was required to recruit MCC-CDC20 to the APC/C (ref. 13) , and APC8 required APC6 to incorporate into the APC/C (Fig. 1d) . To decrease the level of APC/C activity directly we depleted APC10, which should primarily affect activity in metaphase 13 , and APC11, which should inactivate the APC/C entirely 36,37 . Depleting APC11, but not APC10, stabilized CDC20 and cyclin A during SAC signalling (Fig. 7a) . Depleting APC11 also increased the amount of MCCs on the APC/C when the SAC was imposed by DMA, although to a lesser extent than APC15 depletion (Fig. 7b,c) . When cells were released from this arrest into fresh medium containing reversine and MG132, fewer MCCs dissociated from the APC/C in the absence of APC11 when compared with control APC/C (Fig. 7d and Supplementary Fig. S8c ).
To confirm that APC/C ubiquitylation activity was required for the release of MCCs we depleted UbcH10, an E2 specifically used by the APC/C (refs 22,38). Depleting UbcH10 enriched MAD2 and BUB3 on the APC/C to a similar extent as depleting APC11 but had no effect on the dissociation of MCCs (Fig. 7c,e and Supplementary  Fig. S8e ). As a result, by the end of the time course the APC/C from UbcH10-depleted cells contained only slightly elevated amounts of BUBR1, MAD2 and BUB3 when compared with control cells (Fig. 7e and Supplementary Fig. S8d ). This was in agreement with our observation that depleting UbcH10 in vivo had little or no effect on mitosis in cycling cells 39 . Thus, although CDC20 ubiquitylation was irrelevant to the release of MCCs, the effect of depleting APC11 and UbcH10 indicated that other proteins might have to be ubiquitylated for MCC turnover on the APC/C.
DISCUSSION
We have identified an APC/C subunit that is primarily required for the turnover of checkpoint complexes on the APC/C and thus the responsiveness of the SAC. The turnover of MCCs on the APC/C during SAC signalling continuously generates APC/C devoid of MCCs and CDC20 (apo-APC/C; ref. 27) that would be available for the rapid activation of the APC/C when the SAC is satisfied. In the absence of APC15 the MCC remains 'locked' onto the APC/C with ubiquitylated CDC20, causing MCCs that are not yet bound to the APC/C to accumulate. Our evidence indicates that p31 comet has an important role in the turnover of these unbound MCCs ( Supplementary Fig. S9a,b) .
That the phenotype of APC15 depletion depends on SAC signalling might indicate that depleting APC15 itself imposes the SAC, or that APC/C activity is compromised and countered by abrogating the SAC. However, several lines of evidence argue against these possibilities. It is unlikely that APC15 depletion activates the SAC, because inactivating the SAC after MCCs have been recruited to the APC/C has no effect on the APC15-dependent delay in mitosis: only abrogating the SAC before mitosis rescues APC15 depletion. Several lines of evidence show that depleting APC15 does not compromise APC/C activity: the degradation of cyclin A is hardly affected in the absence of APC15; the kinetics of cyclin-B1 destruction is identical to controls in the absence of the SAC; APC15 is not required for APC/C activity in vitro; and CDC20 ubiquitylation is not affected by APC15 depletion although CDC20 itself is stabilized, possibly because it cannot be released from the APC/C to be degraded by the proteasome. In contrast, directly inactivating the APC/C by depleting APC11 stabilizes both CDC20 and cyclin A. We note that APC15 deletions in S. pombe or in S. cerevisiae 6, 7 also show that APC15 is not required for APC/C activity.
How APC15 promotes the release of MAD2 and BUB3 from the APC/C is not clear, but we can conclude that CDC20 ubiquitylation is not required because we find ubiquitylated CDC20 on the APC/C in the absence of APC15; indeed, both MAD2 and ubiquitylated CDC20 simultaneously accumulate on the APC/C. Furthermore, replacing endogenous CDC20 with a non-ubiquitylatable mutant does not affect the release of MCCs from the APC/C. Instead, as we previously suggested, the ubiquitylation of CDC20 may be important to target CDC20 for proteolysis to maintain the SAC and prevent the possibility that increasing amounts of CDC20 could overcome the SAC (refs 5,16 ). The alternative model, that CDC20 ubiquitylation drives the disassembly of the MCC, raises some conceptual problems: the constant generation of ubiquitylated CDC20, which would be insensitive to the SAC (ref. 4) , might immediately activate the APC/C. To resolve this, CDC20 has been reported to be deubiquitylated by USP44 (ref. 40), but this would generate a futile cycle because this CDC20 would now be able to activate the APC/C. Our data indicate that a factor other than CDC20 might need to be ubiquitylated because depleting UbcH10 increases the amounts of MAD2 and BUB3 on the APC/C during SAC signalling and APC11 depletion prevents the release of MCCs from the APC/C. BUBR1 is one attractive candidate because we previously showed that it can be ubiquitylated by the APC/C in vitro 22 , which might be important for progress through mitosis 41 . Nonetheless, although polyubiquitylation seems to be required to release MCCs (refs 4,33), proteolysis is not 4, 5, 27, 33 . In contrast to APC11, inactivating the APC/C by depleting APC3 does not increase the amounts of MCCs on the APC/C, and depleting APC10 slightly decreases MCCs on the APC/C. This may indicate that APC3 contributes to the stability of the interaction between the MCC and the APC/C, perhaps through recruiting APC10 (ref. 13) .
A clue to how APC15 regulates CDC20-MCC binding and release might be gleaned from studies in S. cerevisiae. Although not essential for vegetative divisions, deleting Mnd2 increases the binding of the meiotic co-activator Ama1 to the APC/C (ref. 42). APC15 might, therefore, modulate CDC20-MCC binding to prevent it 'locking' onto the APC/C. Alternatively, APC15 might present MCC-CDC20 as a substrate to the APC/C or recruit a release factor. APC15 is located in the right position on the APC/C to influence the binding of the MCC because it seems to interact with APC8, which in turn is needed to bind CDC20-MCC (ref. 13) .
Last, as the function of APC15 in human cells seems to be primarily linked to the SAC and its depletion prevents mitotic slippage, APC15 may be a candidate for chemotherapeutic drugs.
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The authors declare no competing financial interests. cleavage site into pet30a (Novagen). Tetracycline-inducible cell lines expressing APC15-IRES2-mRuby, APC15-3×Flag or cyclin B1-L45A-HA were generated using the FLIP-in system and a modified pCDNA5/FRT/TO vector (Invitrogen). CDC20 K485/490R was generated by site-directed mutagenesis of wild-type CDC20 (ref. 5). The parental tetracycline-inducible RPE1 cell line was created by random integration of an FRT site and a Tet repressor (Invitrogen) gene into RPE1 cells. The tetracyclin-inducible HeLa cell line was a gift from S. Taylor (University of Manchester, UK). For siRNA-rescue experiments HeLa and RPE1 cell lines were induced with tetracycline (1 µg ml −1 ) for 12 h (CDC20 siRNA) or 72 h (APC15 siRNA) before analysis, respectively. RPE1 cyclin-B1-Venus and cyclin-A2-Venus cell lines were generated by gene targeting 44 using a modified protocol (Collin et al., manuscript in preparation).
M E T H O D S
Cell culture and synchronization. HeLa cells were maintained in Advanced DMEM supplemented with 10% FCS and penicillin/streptavidin. RPE1 cells were cultured in F12/DMEM (1:1) media supplemented with 10% FCS, sodium bicarbonate, glutamate and penicillin/streptavidin. Synchronization in different cellcycle phases was always preceded by a standard double-thymidine (2.5 mM) block and release protocol. For G2 phase and G1 phase, cells were released into DMEM for 5 or 18 h, respectively. Prometaphase cells were collected by mitotic shake-off 14 h after release into DMA (10 µM), or released for a further 2 h into MG132 (10 µM) to obtain a metaphase arrest. To block cells in anaphase, non-degradable cyclin-B1 L45A was induced at the final release from a double-thymidine block. Cells were released for 12 h into DMA and then released for a further 80 min into fresh DMEM and collected by mitotic shake-off. Cycling RPE1 cells were treated with DMA (20 µM), reversine (0.5 µM) or ZM447439 (4 µM). For mitotic slippage studies, cycling RPE1 cells were arrested in mitosis with taxol (5 µM).
RNA interference. RPE1 and HeLa cells were transfected with Lipofectamine
RNAiMAX (Invitrogen) and siRNA oligonucleotides at 50 nM for 85 h before analysis by immunoprecipitation or microscopy unless stated otherwise. For APC10-, APC11-and UbcH10-depletion, cells were transfected twice: 12 h before the start, and after the first release during a double-thymidine synchronization protocol. APC6, APC8, APC10 and APC11 were transfected with a 1:1 mixture of oligonucleotides 1 and 2. For experiments characterizing the function of APC15, oligonucleotide 4 was used. Control and p31 comet oligonucleotides were purchased from Invitrogen: GAPDH D-001830-01, p31 comet oligonucleotide 1 (5 -UUCUUCGGACUUCUCAUACCACUCC-3 ) and p31 comet oligonucleotide 2 (5 -CCGCAACUGUGGAGAAGAUUGGUUU-3 ). APC15 oligonucleotides were purchased from Sigma: APC15 oligonucleotide 1 (5 -CUGAGACUCUGUGGUUUAA-3 ), APC15 oligonucleotide 2 (5 -GCCAUCAGUCUGCACUUGA-3 ), APC15 oligonucleotide 3 (5 -CGAGAUGAAUGACUACAAU-3 ), APC15 oligonucleotide 4 (5 -GUCUGGUCUAAGUUUCUUU-3 ) and APC15 oligonucleotide 6 (5 ;-GGAUCGACCCUGUGUGGAA-3 ). The remaining oligonucleotides were obtained from Dharmacon: APC3 (5 -GGAAAUAGCCGAGAGGUAAUU-3 ), MAD2 (5 -GGAAGAGUCGGGACCACAGUU-3 ), CDC20 (5 -CGGAAGACCUGCCGUU-ACAUU-3 ), APC11 oligonucleotide 1 (5 -UCUGCAGGAUGGCAUUUAAUU-3 ), APC11 oligonucleotide 2 (5 -AAGAUUAAGUGCUGGAACGUU-3 ), APC10 oligonucleotide 1 (5 -GAGCUCCAUUGGUAAAUUUUU-3 ), APC10 oligonucleotide 2 (5 -GAAAUUGGGUCACAAGCUGUU-3 ), APC6 oligonucleotide 1 (5 -CUAUGGACCUGCAUGGAUAUU-3 ), APC6 oligonucleotide 2 (5 -CGAGGUAACAGUUGACAAAUU-3 ), APC8 oligonucleotide 1 (5 -GAAAUUAAAUCCUCGGUAUUU-3 ), APC8 oligonucleotide 2 (5 -GCAGUUGC-CUAUCACAAUAUU-3 ) and UbcH10 oligonucleotide (5 -GGUAUAAGCUCUC-GCUAGATT-3 ).
Microscopy. Before imaging, the culture medium was replaced with Leibovitz's L-15 medium (Gibco BRL) supplemented with 10% fetal bovine serum and penicillin/streptomycin. RPE1 and HeLa cells were imaged on a DeltaVision micrososcope (API) or an ImageXpress Micro wide-field system (Molecular Devices). Images were captured at 3 min intervals and the fluorescence intensities were measured and analysed using ImageJ software as previously described 11 . For presentation, noise reduction was applied using the Sigma filter of the ImageJ software. Statistical analysis was carried out using Prism 4 software (Graphpad Software). The data were visualized on scatter dot blots showing the mean.
Protein expression, antibodies and quantitative immunoblotting. Polyclonal antibodies were generated by Moravian Biotechnology against full-length His-TEV-hAPC15 purified from BL21 Escherichia coli using standard techniques. Epitope tags were removed by TEV cleavage before immunization. Expression and purification of proteins used for in vitro ubiquitylation reactions were carried out as previously described 22 . The following antibodies were used at the indicated dilution: APC15 (polyclonal antibody raised against full-length APC15, 1:500), CDC20 (sc-13162, 1:250; Santa Cruz Biotechnology), CDC20 (sc5296, for immunoprecipitations alone; Santa Cruz Biotechnology), MAD2 (Clone AS55-A12, 1:500; gift from A. Musacchio, IFOM, Milan, Italy), MAD2 (A300-301A; 1:1000, Bethyl Laboratories), p31 comet (Clone E29.19.14, 1:200; gift from A. Musacchio), BUBR1 (A300-386A, 1:1,000; Bethyl Laboratories), BUB3 (611730, 1:500; BD Transduction Laboratories), cyclin B1 (monoclonal antibody GNS-1, 1:2,000; BD Pharmingen), cyclin A2 (monoclonal antibody raised against a N-terminal peptide, 1:1,000), phospho-H3 S10 (14, Immunoprecipitation and size-exclusion chromatography. Cells were lysed for 25 min on ice in extraction buffer A (50 mM Tris-HCl at pH 8.0, 150 mM NaCl, 0.5 % NP-40, 1 mM dithiothreitol, Roche complete inhibitor cocktail tablet, 0.2 µM microcystin and 1 mM phenylmethyl sulphonyl fluoride) and lysates were cleared by centrifugation (15 min, 16,100g ) . Protein complexes were precipitated with antibodies covalently coupled to Dynabeads (Invitrogen), washed in extraction buffer and bound proteins were eluted by LDS-sample buffer (Invitrogen). Sizeexclusion chromatography was carried out on a Superose 6 PC 3.2/30 column (GE Healthcare) as previously described 5 using cells resuspended in buffer B (175 mM NaCl, 30 mM HEPES at pH 7.8, 2.5 mM MgCl 2 , 10% glycerol, 1 mM dithiothreitol, 0.2 µM microcystin and 1 mM phenylmethyl sulphonyl fluoride).
In vitro ubiquitylation assays and in vitro dissociation of checkpoint proteins. In vitro ubiquitylation assays were carried out as described previously 22 using APC/C immobilized on APC4 or APC3 beads. Ubiquitylation reactions contained ubiquitin-activating enzyme E1, UbcH10, Ube2S, CDC20, ubiquitin, ATP, ATP-regenerating system and radiolabelled cyclin B1 (amino acids 1-86) as a substrate in QPIP buffer (50 mM PIPES at pH 7.5, 100 mM NaCl, 2 mM MgCl 2 , 10% glycerol, 1 mM dithiothreitol and 1 mM EGTA). Mock reactions were carried out in QPIP buffer containing 1 µg µl −1 BSA. Dissociation experiments were carried out without ( Supplementary Fig. S6c, mock reactions) or with unlabelled substrate (Fig. 5c) .
Statistics. Statistical analyses were carried out using GraphPad Prism. The significance of data derived from single-cell destruction assays was determined using unpaired, two-tailed Mann-Whitney tests. Binding to APC/C or CDC20 immunoprecipitates was analysed by paired, two-tailed Student's t -tests. The results are summarized in Supplementary Table S1 . 
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